SEARCH

SEARCH BY CITATION

References

  • 1
    Bishop JR, Schuksz M & Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 10301037.
  • 2
    Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J & Zako M (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68, 729777.
  • 3
    Iozzo RV & Sanderson RD (2011) Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 15, 10131031.
  • 4
    Theocharis AD, Skandalis SS, Tzanakakis GN & Karamanos NK (2010) Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 277, 39043923.
  • 5
    Kramer KL & Yost HJ (2003) Heparan sulfate core proteins in cell-cell signaling. Annu Rev Genet 37, 461484.
  • 6
    Sasisekharan R, Shriver Z, Venkataraman G & Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2, 521528.
  • 7
    Belting M (2003) Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem Sci 28, 145151.
  • 8
    Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM & Bernfield M (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691697.
  • 9
    Vlodavsky I, Miao HQ, Medalion B, Danagher P & Ron D (1996) Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 15, 177186.
  • 10
    Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12, 8998.
  • 11
    Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L & Kovalszky I (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12, 173186.
  • 12
    Vreys V & David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11, 427452.
  • 13
    Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I & Vlodavsky I (2001) Heparanase as mediator of angiogenesis: mode of action. FASEB J 15, 16611663.
  • 14
    Gotte M (2003) Syndecans in inflammation. FASEB J 17, 575591.
  • 15
    Li JP & Vlodavsky I (2009) Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 102, 823828.
  • 16
    Ilan N, Elkin M & Vlodavsky I (2006) Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int J Biochem Cell Biol 38, 20182039.
  • 17
    Parish CR, Freeman C & Hulett MD (2001) Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471, M99M108.
  • 18
    Bar-Sela G, Kaplan-Cohen V, Ilan N, Vlodavsky I & Ben-Izhak O (2006) Heparanase expression in nasopharyngeal carcinoma inversely correlates with patient survival. Histopathology 49, 188193.
  • 19
    Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsky I & Nagler R (2006) Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 8, 879884.
  • 20
    Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N & Vlodavsky I (2006) Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 8, 10551061.
  • 21
    Koliopanos A, Friess H, Kleeff J, Shi X, Liao Q, Pecker I, Vlodavsky I, Zimmermann A & Buchler MW (2001) Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res 61, 46554659.
  • 22
    Takaoka M, Naomoto Y, Ohkawa T, Uetsuka H, Shirakawa Y, Uno F, Fujiwara T, Gunduz M, Nagatsuka H, Nakajima M et al. (2003) Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest 83, 613622.
  • 23
    Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz M & Tanaka N (2005) The role of heparanase in gastrointestinal cancer (Review). Oncol Rep 14, 38.
  • 24
    Nobuhisa T, Naomoto Y, Ohkawa T, Takaoka M, Ono R, Murata T, Gunduz M, Shirakawa Y, Yamatsuji T, Haisa M et al. (2005) Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol 131, 229237.
  • 25
    Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ et al. (2005) Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105, 13031309.
  • 26
    Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R, Peretz T, Vlodavsky I & Abramovitch R (2006) Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 118, 16091617.
  • 27
    Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I & Elkin M (2008) Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res 14, 668676.
  • 28
    Edovitsky E, Elkin M, Zcharia E, Peretz T & Vlodavsky I (2004) Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 96, 12191230.
  • 29
    Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG & Marchetti D (2005) Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia 7, 253262.
  • 30
    Meirovitz A, Hermano E, Lerner I, Zcharia E, Pisano C, Peretz T & Elkin M (2011) Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 71, 27722780.
  • 31
    Xiong Z, Lu MH, Fan YH, Cao YL, Hu CJ, Wu YY, Wang SM, Luo G, Fang DC, Li C et al. (2012) Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int J Oncol 40, 16011609.
  • 32
    He YQ, Sutcliffe EL, Bunting KL, Li J, Goodall KJ, Poon IK, Hulett MD, Freeman C, Zafar A, McInnes RL et al. (2012) The endoglycosidase heparanase enters the nucleus of T lymphocytes and modulates H3 methylation at actively transcribed genes via the interplay with key chromatin modifying enzymes. Transcription 3, 130145.
  • 33
    Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B & Vlodavsky I (2003) Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 17, 10151025.
  • 34
    Zetser A, Bashenko Y, Miao HQ, Vlodavsky I & Ilan N (2003) Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63, 77337741.
  • 35
    Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I & Ilan N (2004) Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279, 2353623541.
  • 36
    Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I & Ilan N (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66, 14551463.
  • 37
    Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I & Ilan N (2008) Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68, 1007710085.
  • 38
    Purushothaman A, Babitz SK & Sanderson RD (2012) Heparanase enhances the insulin receptor signaling pathway to activate ERK in multiple myeloma. J Biol Chem 287, 4128841296.
  • 39
    Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, Parish CR & Smith PN (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58, 15901600.
  • 40
    Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I & Ilan N (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20, 814.
  • 41
    Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R, Doviner V, Rubinstein AM, Ishai-Michaeli R, Atzmon R, Sherman Y et al. (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121, 17091721.
  • 42
    Zhang X, Wang B, O'Callaghan P, Hjertstrom E, Jia J, Gong F, Zcharia E, Nilsson LN, Lannfelt L, Vlodavsky I et al. (2012) Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain. Acta Neuropathol 124, 465478.
  • 43
    Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX et al. (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 18, 12171223.
  • 44
    Rao G, Ding HG, Huang W, Le D, Maxhimer JB, Oosterhof A, van Kuppevelt T, Lum H, Lewis EJ, Reddy V et al. (2011) Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia 54, 15271538.
  • 45
    Osterholm C, Folkersen L, Lengquist M, Ponten F, Renne T, Li J & Hedin U (2013) Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 226, 6773.
  • 46
    Ostrovsky O, Shimoni A, Rand A, Vlodavsky I & Nagler A (2010) Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. Blood 115, 23192328.
  • 47
    Levidiotis V, Freeman C, Punler M, Martinello P, Creese B, Ferro V, van der Vlag J, Berden JH, Parish CR & Power DA (2004) A synthetic heparanase inhibitor reduces proteinuria in passive Heymann nephritis. J Am Soc Nephrol 15, 28822892.
  • 48
    Levidiotis V, Freeman C, Tikellis C, Cooper ME & Power DA (2005) Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. Nephrology (Carlton) 10, 167173.
  • 49
    Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP et al. (2012) Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes 61, 208216.
  • 50
    Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I & Weinstein T (2012) Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One 7, e44076.
  • 51
    Ziolkowski AF, Popp SK, Freeman C, Parish CR & Simeonovic CJ (2012) Heparan sulfate and heparanase play key roles in mouse beta cell survival and autoimmune diabetes. J Clin Invest 122, 132141.
  • 52
    Zcharia E, Jia J, Zhang X, Baraz L, Lindahl U, Peretz T, Vlodavsky I & Li JP (2009) Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 4, e5181.
  • 53
    McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C et al. (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276, 11701177.
  • 54
    Levy-Adam F, Feld S, Cohen-Kaplan V, Shteingauz A, Gross M, Arvatz G, Naroditsky I, Ilan N, Doweck I & Vlodavsky I (2010) Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 285, 2801028019.
  • 55
    Matzner Y, Bar-Ner M, Yahalom J, Ishai-Michaeli R, Fuks Z & Vlodavsky I (1985) Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 76, 13061313.
  • 56
    Temkin V, Aingorn H, Puxeddu I, Goldshmidt O, Zcharia E, Gleich GJ, Vlodavsky I & Levi-Schaffer F (2004) Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J Allergy Clin Immunol 113, 703709.
  • 57
    Ateeq B, Unterberger A, Szyf M & Rabbani SA (2008) Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10, 266278.
  • 58
    Shteper PJ, Zcharia E, Ashhab Y, Peretz T, Vlodavsky I & Ben-Yehuda D (2003) Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 22, 77377749.
  • 59
    Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA et al. (2005) Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11, 10281036.
  • 60
    Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA et al. (2005) Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 24, 67656772.
  • 61
    Baraz L, Haupt Y, Elkin M, Peretz T & Vlodavsky I (2006) Tumor suppressor p53 regulates heparanase gene expression. Oncogene 25, 39393947.
  • 62
    de Mestre AM, Khachigian LM, Santiago FS, Staykova MA & Hulett MD (2003) Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 278, 5037750385.
  • 63
    de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM & Hulett MD (2005) Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 280, 3513635147.
  • 64
    Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA & Xu X (2002) Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 277, 89898998.
  • 65
    Lu WC, Liu YN, Kang BB & Chen JH (2003) Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 22, 919923.
  • 66
    Rao G, Liu D, Xing M, Tauler J, Prinz RA & Xu X (2010) Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation. Neoplasia 12, 946956.
  • 67
    Maxhimer JB, Quiros RM, Stewart R, Dowlatshahi K, Gattuso P, Fan M, Prinz RA & Xu X (2002) Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 132, 326333.
  • 68
    Elkin M, Cohen I, Zcharia E, Orgel A, Guatta-Rangini Z, Peretz T, Vlodavsky I & Kleinman HK (2003) Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 63, 88218826.
  • 69
    Xu X, Ding J, Rao G, Shen J, Prinz RA, Rana N & Dmowski WP (2007) Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. Hum Reprod 22, 927937.
  • 70
    Chen G, Wang D, Vikramadithyan R, Yagyu H, Saxena U, Pillarisetti S & Goldberg IJ (2004) Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry 43, 49714977.
  • 71
    Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I & Elkin M (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107, 36093616.
  • 72
    Hermano E, Lerner I & Elkin M (2012) Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci 15, 25012513.
  • 73
    Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I & Ilan N (2003) Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308, 885891.
  • 74
    McKenzie E, Young K, Hircock M, Bennett J, Bhaman M, Felix R, Turner P, Stamps A, McMillan D, Saville G et al. (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373, 423435.
  • 75
    Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A & Steinkuhler C (2004) Mechanism of activation of human heparanase investigated by protein engineering. Biochemistry 43, 18621873.
  • 76
    Abboud-Jarrous G, Rangini-Guetta Z, Aingorn H, Atzmon R, Elgavish S, Peretz T & Vlodavsky I (2005) Site-directed mutagenesis, proteolytic cleavage, and activation of human proheparanase. J Biol Chem 280, 1356813575.
  • 77
    Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB, Joyce JA & Vlodavsky I (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283, 1816718176.
  • 78
    Fridman R, Lider O, Naparstek Y, Fuks Z, Vlodavsky I & Cohen IR (1987) Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix. J Cell Physiol 130, 8592.
  • 79
    Vlodavsky I, Eldor A, Haimovitz-Friedman A, Matzner Y, Ishai-Michaeli R, Lider O, Naparstek Y, Cohen IR & Fuks Z (1992) Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 12, 112127.
  • 80
    Lider O, Baharav E, Mekori YA, Miller T, Naparstek Y, Vlodavsky I & Cohen IR (1989) Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 83, 752756.
  • 81
    Naparstek Y, Cohen IR, Fuks Z & Vlodavsky I (1984) Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 310, 241244.
  • 82
    Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Baharav E, Cohen IR & Naparstek Y (1990) Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur J Immunol 20, 493499.
  • 83
    Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T, Zcharia E, Vlodavsky I, Seifert P & Edelman ER (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104, 380387.
  • 84
    Parish CR, Hindmarsh EJ, Bartlett MR, Staykova MA, Cowden WB & Willenborg DO (1998) Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. Immunol Cell Biol 76, 104113.
  • 85
    Irony-Tur-Sinai M, Vlodavsky I, Ben-Sasson SA, Pinto F, Sicsic C & Brenner T (2003) A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation. J Neurol Sci 206, 4957.
  • 86
    Floer M, Gotte M, Wild MK, Heidemann J, Gassar ES, Domschke W, Kiesel L, Luegering A & Kucharzik T (2010) Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol 176, 146157.
  • 87
    Xavier RJ & Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427434.
  • 88
    Clayburgh DR, Shen L & Turner JR (2004) A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest 84, 282291.
  • 89
    Belmiro CL, Souza HS, Elia CC, Castelo-Branco MT, Silva FR, Machado RL & Pavao MS (2005) Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int J Colorectal Dis 20, 295304.
  • 90
    Bode L, Salvestrini C, Park PW, Li JP, Esko JD, Yamaguchi Y, Murch S & Freeze HH (2008) Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function. J Clin Invest 118, 229238.
  • 91
    Murch SH, MacDonald TT, Walker-Smith JA, Levin M, Lionetti P & Klein NJ (1993) Disruption of sulphated glycosaminoglycans in intestinal inflammation. Lancet 341, 711714.
  • 92
    Day R & Forbes A (1999) Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease. Lancet 354, 6265.
  • 93
    Day R, Ilyas M, Daszak P, Talbot I & Forbes A (1999) Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy. Dig Dis Sci 44, 25082515.
  • 94
    Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, Sabo E, Cohen-Kaplan V, Petcherski S, Avniel-Polak S, Eitan A et al. (2012) Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33, 5665.
  • 95
    Brunn GJ, Bungum MK, Johnson GB & Platt JL (2005) Conditional signaling by Toll-like receptor 4. FASEB J 19, 872874.
  • 96
    Weinbaum S, Tarbell JM & Damiano ER (2007) The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9, 121167.
  • 97
    Constantinescu AA, Vink H & Spaan JA (2003) Endothelial cell glycocalyx modulates immobilization of leukocytes at the endothelial surface. Arterioscler Thromb Vasc Biol 23, 15411547.
  • 98
    Massena S, Christoffersson G, Hjertstrom E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP & Phillipson M (2010) A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116, 19241931.
  • 99
    Li L, Wang B, Gao T, Zhang X, Hao JX, Vlodavsky I, Wiesenfeld-Hallin Z, Xu XJ & Li JP (2012) Heparanase overexpression reduces carrageenan-induced mechanical and cold hypersensitivity in mice. Neurosci Lett 511, 47.
  • 100
    Ledin J, Staatz W, Li JP, Gotte M, Selleck S, Kjellen L & Spillmann D (2004) Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem 279, 4273242741.
  • 101
    Allen BL, Filla MS & Rapraeger AC (2001) Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition. J Cell Biol 155, 845858.
  • 102
    Guo CH, Koo CY, Bay BH, Tan PH & Yip GW (2007) Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour. Int J Oncol 31, 14151423.
  • 103
    Young E (2008) The anti-inflammatory effects of heparin and related compounds. Thromb Res 122, 743752.
  • 104
    Escobar Galvis ML, Jia J, Zhang X, Jastrebova N, Spillmann D, Gottfridsson E, van Kuppevelt TH, Zcharia E, Vlodavsky I, Lindahl U et al. (2007) Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat Chem Biol 3, 773778.
  • 105
    Nakajima M, Irimura T, Di Ferrante N & Nicolson GL (1984) Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 259, 22832290.
  • 106
    Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y & Schirrmacher V (1983) Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res 43, 27042711.
  • 107
    Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M et al. (2007) Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109, 49144923.
  • 108
    Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I & Sherman Y (2006) Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 19, 878888.
  • 109
    Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I et al. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5, 793802.
  • 110
    Jiang G, Zheng L, Pu J, Mei H, Zhao J, Huang K, Zeng F & Tong Q (2012) Small RNAs targeting transcription start site induce heparanase silencing through interference with transcription initiation in human cancer cells. PLoS One 7, e31379.
  • 111
    Joyce JA, Freeman C, Meyer-Morse N, Parish CR & Hanahan D (2005) A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24, 40374051.
  • 112
    Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC & Sanderson RD (2010) Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 115, 24492457.
  • 113
    Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy JD Jr, Sawyer J, Li JP, Zcharia E, Vlodavsky I et al. (2007) Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 282, 1332613333.
  • 114
    Ramani VC, Yang Y, Ren Y, Nan L & Sanderson RD (2011) Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity. J Biol Chem 286, 64906499.
  • 115
    Grivennikov SI & Karin M (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20, 6571.
  • 116
    Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646674.
  • 117
    Mantovani A, Allavena P, Sica A & Balkwill F (2008) Cancer-related inflammation. Nature 454, 436444.
  • 118
    Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A & Domellof L (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328, 14331437.
  • 119
    Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C & Ullman T (2007) Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 133, 10991105; quiz 1340-1.
  • 120
    Brun R, Naroditsky I, Waterman M, Ben-Izhak O, Groisman G, Ilan N & Vlodavsky I (2009) Heparanase expression by Barrett's epithelium and during esophageal carcinoma progression. Mod Pathol 22, 15481554.
  • 121
    Qian BZ & Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141, 3951.
  • 122
    Picardo SL, Maher SG, O'Sullivan JN & Reynolds JV (2012) Barrett's to oesophageal cancer sequence: a model of inflammatory-driven upper gastrointestinal cancer. Dig Surg 29, 251260.
  • 123
    Chiba T, Marusawa H & Ushijima T (2012) Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 143, 550563.
  • 124
    Sonoda R, Naomoto Y, Shirakawa Y, Fujiwara Y, Yamatsuji T, Noma K, Tanabe S, Takaoka M, Gunduz M, Tsujigiwa H et al. (2010) Preferential up-regulation of heparanase and cyclooxygenase-2 in carcinogenesis of Barrett's oesophagus and intestinal-type gastric carcinoma. Histopathology 57, 90100.
  • 125
    El-Assal ON, Yamanoi A, Ono T, Kohno H & Nagasue N (2001) The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin Cancer Res 7, 12991305.
  • 126
    Zhang Y, Li L, Wang Y, Zhang J, Wei G, Sun Y & Shen F (2007) Downregulating the expression of heparanase inhibits the invasion, angiogenesis and metastasis of human hepatocellular carcinoma. Biochem Biophys Res Commun 358, 124129.
  • 127
    Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Drebber U, Baldus SE, Klein E, Azuma M, Metzger R, Hoffmann C et al. (2008) High expression of heparanase is significantly associated with dedifferentiation and lymph node metastasis in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA and via HIF1a to HB-EGF and bFGF. J Gastrointest Surg 12, 16741681; discussion 1681-2.
  • 128
    Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA & Vlodavsky I (1999) Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 83, 424431.
  • 129
    Ferro V, Hammond E & Fairweather JK (2004) The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 4, 693702.
  • 130
    Pan W, Miao HQ, Xu YJ, Navarro EC, Tonra JR, Corcoran E, Lahiji A, Kussie P, Kiselyov AS, Wong WC et al. (2006) 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]- urea derivatives as small molecule heparanase inhibitors. Bioorg Med Chem Lett 16, 409412.
  • 131
    Simizu S, Ishida K & Osada H (2004) Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 95, 553558.
  • 132
    Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R & Vlodavsky I (2005) Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280, 1210312113.
  • 133
    McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151, 114.
  • 134
    Ritchie JP, Ramani VC, Ren Y, Naggi A, Torri G, Casu B, Penco S, Pisano C, Carminati P, Tortoreto M et al. (2011) SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res 17, 13821393.
  • 135
    Dredge K, Hammond E, Handley P, Gonda TJ, Smith MT, Vincent C, Brandt R, Ferro V & Bytheway I (2011) PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer 104, 635642.
  • 136
    Zhou H, Roy S, Cochran E, Zouaoui R, Chu CL, Duffner J, Zhao G, Smith S, Galcheva-Gargova Z, Karlgren J et al. (2011) M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 6, e21106.
  • 137
    Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoreto M, Cassinelli G, Lanzi C, Pisano C, Ilan N et al. (2011) Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. J Cell Mol Med 15, 18571864.
  • 138
    van den Hoven MJ, Waanders F, Rops AL, Kramer AB, van Goor H, Berden JH, Navis G & van der Vlag J (2009) Regulation of glomerular heparanase expression by aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant 24, 26372645.
  • 139
    Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H & Andersson R (2011) TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 9, 219.